Travoprost

Drug Profile

Travoprost

Alternative Names: AL 06221; AL-6221; Izba; Travatan; Travatan APS; Travatan Z; Travatanz; Travoprost advanced preservative system; Travoprost APS

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Alcon
  • Class Antiglaucomas; Prostaglandins; Small molecules
  • Mechanism of Action Prostaglandin F2 alpha agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Open-angle glaucoma
  • No development reported Ocular hypertension

Most Recent Events

  • 27 Jan 2017 Novartis has patent protection for travoprost in Europe and Japan (Novartis 20-F filed in 2017)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Ocular-hypertension(In adolescents, In children, In infants) in Saudi Arabia (Ophthalmic, Drops)
  • 24 Dec 2014 Launched for Open angle glaucoma (In adolescents, In children) in European Union, Norway, Iceland and Liechtenstein (Ophthalmic)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top